Ki-67, p53, Bcl-2 and Bax expression in urothelial carcinomas of urinary bladder

Turk Patoloji Dergisi/Turkish Journal of Pathology

Volumn 26, Issue 1, 2010, Pages 25-30

  Şen Türk, Nilay ^a   Aybek, Zafer ^a   Düzcan, Ender ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Bax; Bcl 2; Bladder cancer; Ki 67; p53

Indexed keywords

KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PARAMETER; PROTEIN EXPRESSION;

EID: 77952933400     PISSN: 10185615     EISSN: 13095730     Source Type: Journal    
DOI: 10.5146/tjpath.2010.00991     Document Type: Article

References (21)

1. Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R, Lopez-Beltran A: Ki-67 Mib1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006, 59:83-88 (Pubitemid 43076244)
2. Tumours of the Urinary System. In Eble JN, Sauter G, Epstein JI, Sesterhenn IA. (Eds): Pathology&Genetics. Tumours of the Urinary System and Male Genital Organs. Lyon, iArC Press, 2004, 90-109
3. Rodríguez-Alonso A, Pita-Fernández S, González- Carreró J, Nogueira-March JL: Multivariate analysis of survival, recurrence, progression and development of mestastasis in T1 and T2a transitional cell bladder carcinoma. Cancer 2002, 94: 677-1684 (Pubitemid 34241104)
4. Gontero P, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C, Muir GH, Tizzani A: Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000, 38:287-296
5. Korkolopoulou P, Lazaris ACh, Konstantinidou AE, Kavantzas N, Patsouris E, Christodoulou P, Thomas-Tsagli E, Davaris P: Differential expression of bcl-2 family proteins in bladder carcinomas Relationship with apoptotic rate and survival. Eur Urol 2002, 41:274-283 (Pubitemid 35303425)
6. Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, Bartelink H, Verheij M: Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 2001, 61:169-175 (Pubitemid 33016577)
7. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA: The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998, 29:146-154 (Pubitemid 28099510)
8. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Garcia-Escudero A, Pareja Megia MJ, Montironi R, Lopez-Beltran A: BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Lett 2007, 250:292-299
9. Frank I, Cheville JC, Blute ML, Lohse CM, Karnes RJ, Weaver AL, Sebo TJ, Nehra A, Zincke H: Prognostic value of p53 and Mib-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 2004, 101:1803-1808 (Pubitemid 39314743)
10. Krause FS, Feil G, Bichler KH: İmmunohistochemical examinations (Ki67, p53, nm23) and DnA cytophotometry in bladder cancer. Anticancer Res 2000, 20:5023-5028 (Pubitemid 32319073)
11. Camur NK, Kilicaslan I, Gulluoǧlu MG, Esen T, Uysal V: Impact of p53 and Ki-67 in predicting recurrence abd progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int 2002, 52:463-469 (Pubitemid 34989304)
12. Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ: Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. Anticancer Res 2002, 22:3759-3764 (Pubitemid 36132862)
13. Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E: The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract 1997, 193:767-775 (Pubitemid 28083305)
14. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DG, Cote RJ: Prognostics markers in bladder cancer: a contemporary review of the literature. J Urol 1998, 160:645-659
15. Kausch I, Böhle A: Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol 2002, 41:15-29
16. Leonardo C, Mattace RD, Albino GA, Pozza M, Gallucci M: The role of bcl-2 and bax genes for urinary bladder cancer relapse. Eur Urol Suppl 2 2003, 1:45
17. Kong G, Shin KY, Oh YH, Lee JJ, Park HY, Woo YN, Lee JD: Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol 1998, 37:715-720 (Pubitemid 29066826)
18. Liukkonen TJO, Lipponen PK, Helle M, Jauhiainen KE: Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Finnbladder III Group. Urol Res 1997, 25:1-8
19. Lu QL, Abel P, Foster CS, Lalani EN: bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 1996, 27:102-110 (Pubitemid 26049462)
20. Wolf HK, Stöber C, Hohenfellner R, Leissner J: Prognostic value of p53, p2 /WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumor Biol 2001, 22:328-336 (Pubitemid 32823952)
21. Matsumoto H, Wada T, Fukunaga K, Yoshihiro S, Matsuyama H, Naito K: Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol 2004, 34:124-130 (Pubitemid 43102903)